Many hospitals have implemented warfarin dosing nomograms to improve patient safety. To our knowledge, no study has assessed the impact inpatient warfarin initiation has in both medical and surgical patients, on safety outcomes post discharge. To evaluate the impact of a suggested institutional nomogram for the initiation of warfarin, the primary endpoint was the incidence of bleeding throughout follow up. Secondary endpoints included the composite of INR changes ≥0.5/day and INR >4. Patients were followed for a period of 2 weeks post-discharge. The composite endpoint was evaluated for an effect on reaching therapeutic INR, time to reach therapeutic INR, and bleeding events throughout follow up. A single center retrospective study comparing the safety of adherence vs. non-adherence to a warfarin nomogram. A total of 206 patients were included, 73 patients in the nomogram adherence vs. 133 in the nonadherence arm. There was no difference in the proportion of patients who bled throughout the follow up period, adherence 9.6% vs. nonadherence to the nomogram 13.5%, p = 0.407. There was however a statistical difference in the mean total number of bleeding events, 0.096 (7/73) in the adherence vs. 0.158 (21/133) in the non-adherence arm, p = 0.022. There was also no difference in the composite endpoint, 19.2% in the adherence vs. 28.6% in the non-adherence arm p = 0.180. A positive correlation between the inpatient composite and risk of bleeding throughout follow up was noted. The findings of this study support adherence to the nomogram as opposed to non-adherence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11239-016-1462-0 | DOI Listing |
Front Pharmacol
November 2024
Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong SAR, China.
Objective: This study aims to examine the unresolved drug-drug interactions of warfarin using real-world data.
Methods: Electronic medical records from a hospital in Shanghai, China, were used to summarize drug-related problems (DRPs) among inpatients taking warfarin in 2022. Additionally, adverse event data for warfarin from January 2004 to December 2023 were extracted from the U.
Geriatr Orthop Surg Rehabil
December 2024
Fiona Stanley Hospital, Murdoch, WA, Australia.
Introduction: The optimal management of patients taking DOAC medications in the perioperative trauma setting is based on limited evidence. Current guidelines recommend withholding DOAC medications 48-72 hours pre-operatively. The objective of this trial was to determine the utility of measuring DOAC levels prior to surgery, evaluate the safety of a cut-off level of <50 ng/mL and to compare the outcomes with time parameters.
View Article and Find Full Text PDFJ Pak Med Assoc
December 2024
Department of Cardiology Medicine, Health Sciences University, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey.
Objective: To investigate the rates of reaching target international normalised ratio levels and the factors affecting these rates in patients undergoing warfarin therapy.
Methods: The prospective cross-sectional study was conducted between 16.08.
Artif Organs
November 2024
US Clinical Development, Medical and Regulatory Affairs, Novonordisk, Rochester, Minnesota, USA.
Background: The objective of this study is to determine the incidence of major bleeding events in patients implanted with continuous flow left ventricular assist devices (CF-LVADs) bridged with enoxaparin (LMWH) compared to intravenous unfractionated heparin (IV UFH) for a subtherapeutic INR on warfarin.
Methods: A single-center, retrospective, cohort study was conducted including patients with CF-LVADs implanted between January 1, 2012 and July 1, 2020 who received at least one inpatient dose or outpatient prescription for LMWH or IV UFH at least 60 days after CF-LVAD implantation. The primary endpoint was the incidence of major bleeding.
J Interv Card Electrophysiol
November 2024
Janssen Scientific Affairs, LLC, a Johnson & Johnson Company, Titusville, NJ, USA.
Background: Atrial fibrillation (AF) and obstructive sleep apnea (OSA) are often comorbid and associated with increased risk of cardiovascular events such as stroke. We evaluated the effectiveness, safety, healthcare resource utilization, and costs of rivaroxaban versus warfarin in patients with nonvalvular AF (NVAF) and comorbid OSA.
Methods: We used the IQVIA PharMetrics Plus adjudicated claims database to evaluate patients with NVAF, OSA, and moderate-to-severe stroke risk who initiated rivaroxaban or warfarin between November 2011 and December 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!